RZLT at a glance
Rezolute, Inc. (RZLT, SEC CIK 1509261) filed its latest 10-K annual report on September 24, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Rezolute, Inc. (RZLT) shares worth $134.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Evans Daron on March 30, 2026 of 10,000 shares at $2.85 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $134.8M · +2 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue nil for 2026 and 2025; no commercial products, no meaningful revenue since inception
- Net loss $77.6M in 2026 vs $74.4M in 2025; operating expenses increased 4% to $83.0M; R&D down 13% to $53.8M; G&A up 59% to $29.2M
- Best performing: R&D expenses down $7.7M (mainly $9.3M manufacturing cost reduction); worst performing: G&A expenses up $10.8M driven by $5.7M compensation and $4.6M business development costs
- Cash & equivalents $10.6M, marketable securities $97.2M; operating cash outflow $64.6M; investing cash outflow $21.1M; financing inflow only $2.3M in 2026 (vs $107.3M in 2025 from equity financings)
- Management expects sufficient capital for 12 months; key near-term events include upLIFT Phase 3 topline data in 2026, FDA review of sunRIZE data ongoing with no timeline, and potential BLA submission mid-2027 for ersodetug
Business Overview
- Core business: Late-stage rare disease company developing therapies for refractory hypoglycemia caused by various hyperinsulinism forms
- New emphasis: Phase 3 results for ersodetug in congenital HI showed significant CGM-based hypoglycemia improvements despite missing primary endpoint
- Strategic update: FDA review ongoing uniquely outside formal meetings, with encouragement to submit comprehensive data for regulatory path determination
- Quantitative highlight: R&D expense $53.8M in 2026 down from $61.5M in prior year; 58 full-time employees, all US-based
- Noteworthy fact: Six of eight participants met primary endpoint in ongoing Phase 3 tumor HI trial, with notable discontinuation of intravenous glucose
Risk Factors
- Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization
- Macroeconomic risk: Potential supply chain delays and cost increases due to inflation, tariffs, and global conflicts impacting raw material availability
- Supply chain risk: Dependence on a limited number of third-party suppliers with no commercial production agreements for raw materials and drug manufacturing
- Competitive risk: Equity investigations and stock price decline following sunRIZE trial failure may hurt financing and competitive positioning
- Financial risk: Net losses $77.6M FY26, $74.4M FY25 with only $10.6M cash and $97.2M debt securities, requiring additional capital within 12 months to sustain operations
AI summary of the RZLT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Management Discussion & Analysis
- Revenue $0, no meaningful revenue since inception in March 2010
- Profitability: operating losses expected for foreseeable future; no margin percentage disclosed
- Best-performing program: tumor HI EAP, 75% of IV dextrose/TPN patients achieved complete discontinuation
- Workforce reduced by 29 employees; $1.5M severance expense in fiscal Q2 2026
- Near-term outlook: upLIFT enrollment and topline results expected in second half of 2026; FDA sunRIZE update also expected then
Risk Factors
- New clinical-trial risk: FDA-permitted upLIFT design modifications may fail to demonstrate efficacy or meet endpoints
- Regulatory risk: FDA may reject additional sunRIZE datasets as inadequate for approval, efficacy, or commercialization
AI summary of the RZLT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- FY2026 and fourth-quarter financial results announced for period ended June 30, 2026
- Detailed results contained in Exhibit 99.1, the attached earnings press release
Item EX-99.1: Item EX-99.1
- Fiscal 2026 net loss widened to $77.6M from $74.4M despite R&D falling to $53.8M
- Cash, equivalents and marketable securities declined to $107.8M from $167.9M, increasing future financing risk
Item 7.01: Regulation FD Disclosure
- Rezolute issued a June 2, 2026 interim update on its upLIFT study
- Disclosure likely relates to clinical-development progress, making trial status the key investor focus
AI summaries of RZLT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RZLT
Don't miss the next RZLT filing
- Alerts as it files. A push when RZLT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RZLT, by share count.
- Ask anything. An AI agent that reads every RZLT filing and answers with sources.
RZLT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Karnawat Sunil Ratilal | F | Sep 2, 2026 | 2,267 | $4.50 |
| Evans Daron | F | Jul 2, 2026 | 3,062 | $4.99 |
| ROBERTS BRIAN KENNETH | F | Jul 2, 2026 | 3,062 | $4.99 |
| Elam Nevan C | F | Jul 2, 2026 | 8,004 | $4.99 |
| Evans Daron | Buy | Mar 30, 2026 | 10,000 | $2.85 |
| ROBERTS BRIAN KENNETH | F | Mar 2, 2026 | 11,439 | $2.99 |
| Elam Nevan C | F | Mar 2, 2026 | 27,618 | $2.99 |
| Evans Daron | F | Mar 2, 2026 | 11,438 | $2.99 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$70.4M | -$79.9M | -$83.0M | |
| Net Income | -$68.5M | -$74.4M | -$77.6M | |
| Balance Sheet | ||||
| Total Assets | $132.7M | $175.5M | $112.8M | |
| Equity | $121.0M | $162.1M | $100.7M | |
| ROE | -56.6% | -45.9% | -77.1% | |
| Per Share | ||||
| EPS | $-1.33 | $-0.98 | $-0.75 | |
| Cash Flow | ||||
| Operating CF | -$57.4M | -$69.1M | -$64.6M | |
Source: XBRL data in Rezolute, Inc. (RZLT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RZLT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $134.8M |
| Q1 2026 | 25 | $84.4M |
| Q4 2025 | 23 | $71.9M |
| Q3 2025 | 23 | $324.5M |
| Q2 2025 | 21 | $131.3M |
| Q1 2025 | 13 | $38.9M |
| Q4 2024 | 10 | $25.9M |
| Q3 2024 | 8 | $14.5M |
- BlackRock+1.40M (+22%)
- Goldman Sachs Group+714.5K (+119%)
- Dimensional Fund Advisors+360.5K (+68%)
- Vanguard Capital Management LLC+313.7K (+9%)
- AQR Capital Management+211.3K (+27%)
- Bank of America Corp−2.24M (-75%)
- Vanguard Portfolio Management LLC−1.60M (-54%)
- Morgan Stanley−1.13M (-41%)
- Millennium Management−1.00M (-66%)
- Two Sigma Investments−399.5K (-48%)
- Blackstone Group+1.08M
- Franklin Resources+104.7K
- Ameriprise Financial+97.7K
- U.S. Bancorp+340
- Renaissance Technologies LLC−157.7K
- Raymond James Financial−10.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RZLT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-K | Sep 24, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Sep 3, 2026 | - | - | - |
| SC 13G | Aug 12, 2026 | - | - | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 8-K | Feb 12, 2026 | - | - | |
| 10-Q | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
| SC 13G | Feb 11, 2026 | - | - | |
| SC 13G | Jan 30, 2026 | - | - | |
| 8-K | Jan 7, 2026 | - | - | |
| SC 13G | Dec 19, 2025 | - | - | |
| SC 13G | Dec 18, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RZLT SEC filings: frequently asked questions
Which institutions hold RZLT stock?
As of June 30, 2026, the largest Rezolute, Inc. (RZLT) holders among the 13F filers tracked by SignalX were BlackRock ($40.1 million), Vanguard Capital Management LLC ($19.9 million), State Street Corp ($9.6 million), D.E. Shaw & Co ($9.6 million), Morgan Stanley ($8.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in RZLT's latest 10-K?
In the 10-K filed September 24, 2026, Rezolute, Inc. (RZLT) flagged: Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization. Macroeconomic risk: Potential supply chain delays and cost increases due to inflation, tariffs, and global conflicts impacting raw material availability. (AI summary of the Risk Factors section.)
What did RZLT report in its latest 8-K?
Rezolute, Inc. (RZLT) filed an 8-K on September 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). FY2026 and fourth-quarter financial results announced for period ended June 30, 2026.
What are the latest RZLT SEC filings?
Rezolute, Inc. (RZLT) filed its latest 10-K annual report on September 24, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on September 3, 2026.
What is RZLT's SEC CIK number?
Rezolute, Inc. (RZLT)'s SEC Central Index Key (CIK) is 1509261. EDGAR lists every RZLT filing under that number.
Ask anything about RZLT
The research agent reads RZLT's filings, financials, insider trades and 13F holders, then answers with sources.